NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

OTC Markets · Biotechnology · USD

Lyra Therapeutics, Inc. (LYRA) Stock Analysis

Lyra Therapeutics, Inc. (LYRA) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

LYRA

$0.20

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LYRA with… →

LYRA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.20
Previous Close
$0.20
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$354.98K
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.89
EPS (ttm)Profit attributable to each share over the last twelve months.
−18.62
Financials (FY)
Revenue (FY)
$398.00K−74.05%
Net Income (FY)
−$28.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.77M
1-Year Return
−97.16%
Dividend and dates
Avg Volume
9.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LYRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−93.51%
2025−70.16%
2024−96.06%
2023+66.88%
2022−27.98%
2021−61.75%
2020 (partial year)−38.58%

As of September 4, 2026.

LYRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$398.00K−$28.92M−7266.1%
2024$1.53M−$93.44M−6090.9%
2023$1.56M−$62.68M−4023.1%
2022$1.36M−$55.28M−4055.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$398.00K—−$29.55M−$28.92M−7266.1%
2024$1.53M—−$60.73M−$93.44M−6090.9%
2023$1.56M—−$65.53M−$62.68M−4023.1%
2022$1.36M—−$54.99M−$55.28M−4055.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LYRA Valuation vs Biotechnology Median

Median of 656 stocks
MetricLYRABiotechnology medianvs median
P/S ratio0.8915.260.1x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Lyra Therapeutics, Inc. (LYRA) at $354.98K. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 27.

LYRA last closed at $0.20 on September 4, 2026. The close was unchanged from the previous session.

Financial Health

In fiscal 2025, Lyra Therapeutics, Inc. reported revenue of $398.00K. That is −74.05% against the prior fiscal year, when revenue was $1.53M. The same year closed with a net loss of $28.92M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −18.62.

Across the 4 fiscal years on file, revenue moves from $1.36M in 2022 to $398.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.89. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −97.16%. Across 5 years the annualized return works out at −78.18%. The reported beta is 0.71. Daily returns over the trailing 6 years annualize to a volatility of 1,778.56%.

Growth & Income

The record shows no dividend for LYRA.

Across the complete calendar years on file, 2023 returned +66.88% and 2024 returned −96.06%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is −93.51%.

Peer Comparison

Lyra Therapeutics, Inc. (LYRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lyra Therapeutics, Inc. LYRA $354.98K —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Lyra Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Visit website →